[1]王云生,张清媛.三阴型乳腺癌靶向治疗研究进展[J].新乡医学院学报,2016,33(9):815-818.[doi:10.7683/xxyxyxb.2016.09.022]
　WANG Yunsheng,ZHANG Qingyuan.Research progress of targeted therapy for triple negative breast cancer[J].Journal of Xinxiang Medical University,2016,33(9):815-818.[doi:10.7683/xxyxyxb.2016.09.022]

点击复制

三阴型乳腺癌靶向治疗研究进展

分享到：

参考文献/References:

［1］　ANDERS C K，CAREY L A.Biology，metastatic patterns，and treatment of patients with triple-negative breast cancer［J］.Clin Breast Cancer，2009，9（Suppl 2）：S73-S81.
［2］　袁中玉，王树森，高岩，等.305 例三阴乳腺癌患者的临床特征及预后因素分析［J］.癌症，2008，27（6）：561-565.
［3］　LEHMANN B D.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies［J］.J Clin Invest，2011，121（7）：2750-2767.
［4］　FONG P C，BOSS D S，YAP T A.Inhibition of poly（ADP-ribose） polymerase in tumors from BRCA mutation carriers［J］.N Engl J Med，2009，361（2）：123-134.
［5］　KRIEGE M，SEYNAEVE C，MEIJERS-HEIJBOER H.Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers［J］.J Clin Oncol，2009，27（23）：3764-3771.
［6］　KRIEGE M，JAGER A，HOONING M J，et al.The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers［J］.Cancer，2012，118（4）：899-907.
［7］　ANDRE F，BACHELOT T，COMMO F，et al.Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer：a multicentre，prospective trial （SAFIR01/ UNICANCER） ［J］.Lancet Oncol，2014，15（3）：267-274.
［8］　LIVASY C A，KARACA G，NANDA R，et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma［J］.Mod Pathol，2006，19（2）：264-271.
［9］　O′SHAUGHNESSY J W D，VUKELJA S J，MCINTYRE K，et al.Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer［J］.Breast Cancer Res Treat，2007，106（Suppl 1）：S32.
［10］　BASELGA J，GOMEZ P，GREIL R，et al.Randomized phase Ⅱ study of the antiepidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer［J］.J Clin Oncol，2013，31（20）：2586-2592.
［11］　DICKLER M N，COBLEIGH M A，MILLER K D，et al.Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer［J］.Breast Cancer Res Treat，2009，115（1）：115-121.
［12］　GUTTERIDGE E，AGRAWAL A，NICHOLSON R，et al.The effects of gefitinib in tamoxifen-resistant and hormone- insensitive breast cancer：a phase Ⅱ study［J］.Int J Cancer，2010，126（8）：1806-1816.
［13］　AME J C，SPENLEHAUER C，DE MURCIA G.The PARP superfamily［J］.Bio Essays，2004，26（8）：882-893.
［14］　FARMER H，MCCABE N，LORD C J，et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy［J］.Nature，2005，434（7035）：917-921.
［15］　O′SHAUGHNESSY J，OSBORNE C，PIPPEN J E，et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer［J］.N Engl J Med，2011，364（3）：205-214.
［16］　SCHECH A，KAZI A，YU S，et al.Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells［J］.Mol Cancer Ther，2015，14（8）：1848-1857.
［17］　KOBOLDT D C，FULTON R S，MCLELLAN M D，et al.Comprehensive molecular portraits of human breast tumours［J］.Nature，2012，490（7418）：61-70.
［18］　JUVEKAR A，BURGA L N，HU H，et al.Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer［J］.Cancer Discov，2012，2（11）：1048-1063.
［19］　FINN R S，BENGALA C，IBRAHIM N，et al.Dasatinib as a single agent in triple-negative breast cancer：results of an open-label phase 2 study［J］.Clin Cancer Res，2011，17（21）：6905-6913.
［20］　KIM E M，MUELLER K，GARTNER E，et al.Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells［J］.J Surg Res，2013，185（1）：231-239.
［21］　HOEFLICH K P，O′BRIEN C，BOYD Z，et al.In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models［J］.Clin Cancer Res，2009，15（14）：4649-4664.
［22］　MAIELLO M R，D′ALESSIO A.EGFR and MEK blockade in triple negative breast cancer cells［J］.J Cell Biochem，2015，116（12）：2778-2785.
［23］　MA C X，CAI S，LI S，et al.Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models［J］.J Clin Invest，2012，122（4）：1541-1552.
［24］　CHEN H W，DU C W，WEI X L，et al.Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer［J］.Curr Mol Med，2013，13（3）：410-416.
［25］　LIANG S，PENG X，LI X，et al.Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin［J］.Oncotarget，2015，6（2）：1020-1030.
［26］　RAHIMI M，GEORGE J，TANG C，et al.EGFR variant-mediated invasion by enhanced cxcr4 expression through transcriptional and post-translational mechanisms［J］.Int J Cancer，2010，12（8）：1850-1860.
［27］　LOI S，SIRTAINE N，PIETTE F，et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy：BIG 02-98［J］.J Clin Oncol，2013，31（7）：860-867.
［28］　VINAYAK S，GRAY R J，ADAMS S，et al.Association of increased tumor-infiltrating lymphocytes （TILs） with immunomodulatory （IM） triple-negative breast cancer （TNBC） subtype and response to neoadjuvant platinum-based therapy in PrECOG0105［J］.J Clin Oncol，2014，32（Suppl 5）：1000.
［29］　STAGG J，ALLARD B.Immunotherapeutic approaches in triple-negative breast cancer：latest research and clinical prospects［J］.Ther Adv Med Oncol，2013，5（3）：169-181.
［30］　SOLIMAN H，KHALIL F，ANTONIA S.PD-L1 expression is increased in a subset of basal type breast cancer cell［J］.PLoS One，2014，9（2）：e88557.
［31］　WANG X，OSADA T，WANG Y，et al.CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer［J］.J Natl Cancer Inst，2010，10（19）：1496-1512.